In this article, we will discuss Sacituzumab govitecan-hziy (Dosage Overview). So, let’s get started.
Locally Advanced or Metastatic Triple-Negative Breast Cancer
sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for
Locally Advanced or Metastatic Urothelial Cancer
Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Use Information
Do NOT substitute sacituzumab govitecan-hziy for or use with other drugs containing irinotecan or its active metabolite SN-38.
Recommended Dose and Schedule
The recommended dose of sacituzumab govitecan-hziy is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity. Do not administer sacituzumab govitecan-hziy at doses greater than 10 mg/kg.
Administer sacituzumab govitecan-hziy as an intravenous infusion only. Do not administer as an intravenous push or bolus.
First infusion: Administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions.
Subsequent infusions: Administer infusion over 1 to 2 hours if prior infusions were tolerated. Observe patients during the infusion and for at least 30 minutes after infusion.